{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:52:53Z","timestamp":1780095173101,"version":"3.54.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jhep.2018.11.005","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T11:50:39Z","timestamp":1547553039000},"page":"314-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Endpoints and patient stratification in clinical trials for alcoholic hepatitis"],"prefix":"10.1016","volume":"70","author":[{"given":"Philippe","family":"Mathurin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Thursz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.11.005_b0005","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1056\/NEJMra0805786","article-title":"Alcoholic hepatitis","volume":"360","author":"Lucey","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.11.005_b0010","article-title":"Treatment of severe alcoholic hepatitis","volume":"074","author":"Thursz","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.11.005_b0015","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28\u202fdays for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.11.005_b0020","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.11.005_b0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.11.005_b0030","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1053\/j.gastro.2016.12.019","article-title":"In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA","volume":"152","author":"Vergis","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.11.005_b0035","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.29240","article-title":"Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study","volume":"66","author":"Louvet","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.11.005_b0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2017.11.017","article-title":"Application of prognostic scores in the STOPAH trial: discriminant function is no longer the optimal scoring system in alcoholic hepatitis","volume":"68","author":"Forrest","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.11.005_b0045","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.hep.2003.09.038","article-title":"Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone","volume":"38","author":"Mathurin","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.11.005_b0050","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.11.005_b0055","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1053\/j.gastro.2015.04.044","article-title":"Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis","volume":"149","author":"Louvet","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.11.005_b0060","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.23837","article-title":"Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3","volume":"52","author":"Ki","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.11.005_b0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"Management of alcohol-related liver disease","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","journal-title":"J Hepatol."},{"key":"10.1016\/j.jhep.2018.11.005_b0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0895-4356(98)00138-3","article-title":"Stratified randomization for clinical trials","volume":"52","author":"Kernan","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jhep.2018.11.005_b0075","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.11.005_b0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2009.04.062","article-title":"Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor","volume":"137","author":"Louvet","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.11.005_b0085","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.27779","article-title":"Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis","volume":"62","author":"Michelena","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.11.005_b0090","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1111\/j.1572-0241.2008.02104.x","article-title":"A new scoring system for prognostic stratification of patients with alcoholic hepatitis","volume":"103","author":"Dominguez","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.11.005_b0095","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/MEG.0000000000000926","article-title":"Predicting short-term and long-term mortality of hospitalized Portuguese patients with alcoholic hepatitis","volume":"29","author":"Fernandes","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818325376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818325376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:36:32Z","timestamp":1759174592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818325376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0168827818325376"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.11.005","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endpoints and patient stratification in clinical trials for alcoholic hepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}